Top reads from the CHEST journal portfolio
Experts discuss new research published in CHEST.
Related Articles
Autofluorescence Imaging of Bronchoscopy in Mounier-Kuhn Syndrome: Negative Autofluorescence Sign
“.” American Journal of Respiratory and Critical Care Medicine, 210(5), pp. 665–668 Author Contributions: Patient management: T.T. Conceptualization: T.T. Image interpretation: T.T. and H.S. Original…
About CHEST Membership | membership – American College of Chest Physicians
CHEST membership offers unlimited opportunities for pulmonary, critical care, and sleep medicine clinicians to hone expertise and build genuine professional relationships while saving you time.
The Health Misinformation Monitor: Vaccine Misinformation Spreads as Children Head Back to School | KFF
This edition highlights vaccine hesitancy and misinformation around MMR (measles, mumps, and rubella) vaccines as children return to school and measles cases resurge in parts…
Grants | American Thoracic Society
The American Thoracic Society is the world’s leading medical society dedicated to accelerating the advancement of global respiratory health through…
The Connection Between Social Security Disability Benefits and Health Coverage Through Medicaid and Medicare | KFF
This analysis examines who was eligible for Medicare and/or Medicaid between 2002 and 2022 because they received disability benefits from one of the country’s Social…
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and…
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
The data from PROMIS-I suggest a clinically important benefit of colistimethate sodium delivered via the I-neb adaptive aerosol delivery system in patients with bronchiectasis and…
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial
Our findings suggested that mirtazapine of doses 15 to 45 mg daily over 56 days does not improve severe breathlessness among patients with COPD or…
Pulmonary Dead Space Monitoring: Identifying Subjects With ARDS at Risk of Developing Right Ventricular Dysfunction
BACKGROUND: ARDS is a highly morbid condition characterized by diffuse pulmonary inflammation, which results in hypoxemic respiratory failure. Approximately 25% of patients with ARDS develop…
Odds for respiratory symptoms in 20s high with smoking before adulthood
Adults aged 28 years faced heightened odds for respiratory symptoms if they began smoking before turning 18 years old, according to a presentation at the…
